HC Wainwright Expects Lower Earnings for Janux Therapeutics

Janux Therapeutics, Inc. (NASDAQ:JANX) – Equities researchers at HC Wainwright decreased their Q1 2025 earnings estimates for Janux Therapeutics in a research report issued to clients and investors on Monday, March 3rd. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.48) per share for the quarter, down from their previous forecast of ($0.46). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.38) per share. HC Wainwright also issued estimates for Janux Therapeutics’ Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.86) EPS, FY2026 earnings at ($1.92) EPS, FY2027 earnings at ($1.77) EPS, FY2028 earnings at $0.28 EPS and FY2029 earnings at $2.82 EPS.

A number of other research analysts have also weighed in on JANX. Leerink Partnrs raised shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a research note on Friday, January 10th. BTIG Research raised their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $200.00 price objective on shares of Janux Therapeutics in a research note on Wednesday, December 11th. Finally, Wedbush reiterated an “outperform” rating and issued a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $88.00.

Janux Therapeutics Stock Up 5.0 %

Shares of NASDAQ JANX opened at $31.50 on Thursday. The firm has a market cap of $1.65 billion, a PE ratio of -26.92 and a beta of 3.16. Janux Therapeutics has a 12-month low of $29.63 and a 12-month high of $71.71. The company’s fifty day simple moving average is $42.23 and its 200 day simple moving average is $47.67.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%.

Institutional Investors Weigh In On Janux Therapeutics

A number of large investors have recently modified their holdings of the business. RA Capital Management L.P. boosted its position in Janux Therapeutics by 13.1% in the 4th quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company’s stock worth $554,977,000 after purchasing an additional 1,200,000 shares in the last quarter. FMR LLC boosted its position in Janux Therapeutics by 10.8% in the 4th quarter. FMR LLC now owns 8,669,941 shares of the company’s stock worth $464,189,000 after purchasing an additional 845,266 shares in the last quarter. Janus Henderson Group PLC boosted its position in Janux Therapeutics by 41.2% in the 4th quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company’s stock worth $190,617,000 after purchasing an additional 1,038,996 shares in the last quarter. Paradigm Biocapital Advisors LP boosted its position in Janux Therapeutics by 46.5% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 3,515,986 shares of the company’s stock worth $188,246,000 after purchasing an additional 1,115,412 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its position in Janux Therapeutics by 47.6% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company’s stock worth $163,926,000 after purchasing an additional 986,750 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Insider Activity

In related news, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $42.29, for a total value of $140,994.86. Following the completion of the sale, the insider now directly owns 82,139 shares in the company, valued at $3,473,658.31. The trade was a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction dated Tuesday, December 24th. The shares were sold at an average price of $56.19, for a total value of $1,404,750.00. Following the completion of the sale, the chief executive officer now owns 217,054 shares of the company’s stock, valued at $12,196,264.26. The trade was a 10.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,002 shares of company stock worth $2,684,703 over the last quarter. Insiders own 29.40% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.